VRX Insider Trading Activity and SEC Form 4 Filings
VRX insider trading summary
No open-market insider purchases or sales of Valeant Pharmaceuticals International, Inc. (VRX) have been reported on SEC Form 4 in the past 12 months.
Latest VRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 15, 2018 | Schutter Richard U De | Director | Buy | $327K (15,000 @ $21.83) |
| May 15, 2018 | Schutter Richard U De | Director | Buy | $218K (10,000 @ $21.80) |
| Mar 13, 2018 | Joseph C Papa | Chairman & CEO | Buy | $482K (30,000 @ $16.05) |
| Mar 13, 2018 | Paul Herendeen | EVP and CFO | Buy | $241K (15,000 @ $16.10) |
| Mar 8, 2018 | Schutter Richard U De | Director | Buy | $153K (10,000 @ $15.34) |
| Mar 6, 2018 | John Paulson | Director | Buy | $108.8M (7,066,629 @ $15.40) |
| Mar 6, 2018 | John Paulson | Director | Sell | $108.8M (7,066,629 @ $15.40) |
| Nov 17, 2017 | Schutter Richard U De | Director | Buy | $143K (10,000 @ $14.33) |
| Nov 16, 2017 | John Paulson | Director | Sell | $5.0M (344,216 @ $14.39) |
| Nov 16, 2017 | John Paulson | Director | Buy | $5.0M (344,216 @ $14.40) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.